(WO200834074) Claims 1. A method for eliminating or substantially reducing non-Hodgkin's lymphoma in a subject comprising administering a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject, such that the subject's immune system reconstitutes without stem cell transplantation, and administering an effective amount of an autologous anti-idiotypic vaccine, thereby to eliminate or substantially reduce non-Hodgkin's lymphoma in the subject. 2. A method for eliminating or substantially reducing Hodgkin's disease in a subject comprising administering a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject, such that the subject's immune system reconstitutes without stem cell transplantation, and administering an effective amount of an autologous anti-idiotypic vaccine, thereby to eliminate or substantially reduce Hodgkin's lymphoma in the subject. 3. A method for eliminating or substantially reducing chronic lymphocytic leukemia in a subject comprising administering a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject, such that the subject's immune system reconstitutes without stem cell transplantation, and administering an effective amount of an autologous anti-idiotypic vaccine, thereby to eliminate or substantially reduce chronic lymphocytic leukemia in the subject. 4. A method for eliminating or substantially reducing multiple myeloma in a subject comprising administering a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject, such that the subject's immune system reconstitutes without stem cell transplantation, and administering an effective amount of an autologous anti-idiotypic vaccine, thereby to eliminate or substantially reduce multiple myeloma in the subject. 5. A method for eliminating or substantially reducing mantle cell lymphoma in a subject comprising administering a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject, such that the subject's immune system reconstitutes without stem cell transplantation, and administering an effective amount of an autologous anti-idiotypic vaccine, thereby to eliminate or substantially reduce mantle cell lymphoma in the subject. 6. A method of any one of claims 1-5, further comprising administering a monoclonal antibody that selectively binds a B-cell specific antigen. 7. The method of claims 1-5, wherein the autologous anti-idiotypic vaccine is administered in conjunction with an effective amount of granulocyte-monocyte colony stimulating factor. 8. The method of claim 6, wherein the B-cell specific antigen is selected from the group consisting of CD3d, CD5, CD6, CD9, CD19, CD20, CD21, CD22, CD23, CD24, CD27, CD28, CD37, CD38, CD40, CD45, CD46, CD48, CD53, CD69, CD70, CD72, CD73, CD79a, CD79b, CD80, CD81, CD83, CD85a, CD85d, CD85e, CD85h, CD85i, CD85j, CD85k, CD86, CD96, CD98, CDlOO, CD121b, CD124, CD127, CD132, CD150, CD152, CD154, CD157, CD166, CD169, CD 179a, CD 179b, CDl 80, CDl 85, CD 196, CD 197, CD205, CDw210a, CD213al, CD257, CD267, CD268, CD269, CD274, CD275, CD276, CD278, CD279, CD300a, CD300c, CD307, CD314, CD316, CD317, CD319, CD320, CDw327, and CD331. 9. The method of claim 6, wherein the monoclonal antibody selectively binds CD-20. 10. The method of claim 6, wherein the monoclonal antibody selectively binds CD-22. 11. The method of any one of claims 1 -5, wherein the lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug is 50 mg/kg/day. 12. The method of any one of claims 1-5, wherein the lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug is administered to the subject for 4 days. 13. The method of any one of claims 1-5, wherein the lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug is 50 mg/kg/day administered for 4 days. 14. The method of any one of claims 1-5, wherein the oxazaphosphorine drug is cyclophosphamide administered in the amount of 50 mg/Kg for 4 days. 15. The method of any one of claims 1-5, wherein the oxazaphosphorine drug is powdered cyclophosphamide or a pharmaceutically acceptable salt, solvate, prodrug, or metabolite thereof. 16. The method of any one of claims 1-5, wherein the oxazaphosphorine drug is lyophilized cyclophosphamide or a pharmaceutically acceptable salt, solvate, prodrug, or metabolite thereof. 17. A method of eliminating or substantially reducing a B-cell derived cancer selected from the group consisting of non-Hodgkin's lymphoma, Hodgkin's lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma in a subject comprising administering (a) a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug to the subject; and (b) administering an effective amount of an autologous anti-idiotypic vaccine, thereby to eliminate or substantially reduce the B-cell derived cancer in the subject. 18. The method of claim 17, further comprising administering an effective amount of a monoclonal antibody that selectively binds a B-cell specific antigen. 19. The method of claim 17, wherein the autologous anti-idiotypic vaccine is administered in conjunction with an effective amount of GM-CSF. 20. A method of eliminating or substantially reducing a B-cell derived cancer selected from the group consisting of non-Hodgkin's lymphoma, Hodgkin's lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma in a subject comprising administering to the subject: (a) a lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug; (b) an effective amount of an autologous anti-idiotypic vaccine in conjunction with an effective amount of GM-CSF; and (c) an effective amount of one or more monoclonal antibodies that selectively bind one or more B-cell specific antigens, thereby to eliminate or substantially reduce the B-cell derived cancer in the subject. 21. The method of claim 20, wherein the lymphocytotoxic but hematopoeitic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug is 50 mg/Kg of cyclophosphamide administered daily for 4 days. 22. The method of claim 20, wherein one or more monoclonal antibodies are selected from antibodies that selectively bind CD3d, CD5, CD6, CD9, CD19, CD20, CD21, CD22, CD23, CD24, CD27, CD28, CD37, CD38, CD40, CD45, CD46, CD48, CD53, CD69, CD70, CD72, CD73, CD79a, CD79b, CD80, CD81, CD83, CD85a, CD85d, CD85e, CD85h, CD85i, CD85J, CD85k, CD86, CD96, CD98, CDlOO, CD121b, CD124, CD127, CD132, CD150, CD152, CD154, CD157, CD 166, CD 169, CD 179a, CD 179b, CDl 80, CDl 85, CD 196, CD 197, CD205, CDw210a, CD213al, CD257, CD267, CD268, CD269, CD274, CD275, CD276, CD278, CD279, CD300a, CD300c, CD307, CD314, CD316, CD317, CD319, CD320, CDw327, or CD331. 23. The method of claim 20, wherein the autologous anti-idiotypic vaccine generates an immune response against a B-cell derived cancer specific antigen. 24. The method of any one of claims 1-5, further comprising administering an effective amount of Mesna.
最新评论
暂无评论。